scholarly journals Clostridium botulinum toxin type A; botulinum neurotoxin type A1 nontoxic-nonhemagglutinin component (ntnH)

2012 ◽  
Vol 5 (10) ◽  
pp. 256-256
Keyword(s):  
Botulinum Toxin ◽  
Clostridium Botulinum ◽  
Botulinum Neurotoxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

STUDIES ON THE ORAL TOXICITY OF CLOSTRIDIUM BOTULINUM TOXIN, TYPE A

1954 ◽  
Vol 32 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Ivan W. Coleman
Keyword(s):  
Botulinum Toxin ◽  
Clostridium Botulinum ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Blood Stream ◽  
Oral Toxicity ◽  
Crude Preparation ◽  
Spray Dried

Three aspects of the reported oral toxicity of Clostridium botulinum toxin, Type A, were investigated. No demonstrable migration of the crystalline toxin from the lumen of the intestine into the blood stream of the dog could be found. Evidence indicating that the crystalline toxin was inactivated by pepsin and chymotrypsin was obtained, but the toxin was found to be resistant to the action of trypsin. Comparison of the oral toxicity and the intraperitoneal toxicity of the crystalline toxin revealed that the product was not orally toxic. A spray-dried crude preparation of the toxin demonstrated a low oral toxicity.

Studies using Clostridium botulinum toxin—Type A

1965 ◽  
Vol 7 (1) ◽  
pp. 84-89 ◽  
Author(s):  
L.G. Hart ◽  
R.L. Dixon ◽  
J.P. Long ◽  
B. Mackay
Keyword(s):  
Botulinum Toxin ◽  
Clostridium Botulinum ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals A Moving Residual Limb: Botulinum Toxin to the Rescue

2020 ◽  
Vol 11 (1) ◽  
pp. 34-37 ◽  
Author(s):  
Marie-Michèle Briand ◽  
Mathieu Boudier-Réveret ◽  
Xavier Rodrigue ◽  
Geneviève Sirois ◽  
Min Cheol Chang
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Neurotoxin ◽  
Rare Complication ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Residual Limb ◽  
Satisfaction Level ◽  
Botulinum Neurotoxin Type A ◽  
Standardized Treatment

AbstractMovement disorders post-amputation are a rare complication and can manifest as the jumping stump phenomenon, a form of peripheral myoclonus. The pathophysiology remains unknown and there is currently no standardized treatment. We describe the case of a 57-year-old male with unremitting stump myoclonus, starting one month after transtibial amputation, in his residual limb without associated phantom or neurological pain. The consequence of the myoclonus was a reduction in prosthetic wearing time. Failure to respond to oral medication led us to attempt the use of botulinum neurotoxin Type A injections in the involved muscles of the residual limb. Injection trials, over a two-year period, resulted in an improvement of movement disorder, an increased prosthetic wearing time and a higher satisfaction level of the patient. Injection of botulinum toxin type A should be considered as an alternative treatment for stump myoclonus to improve prosthetic wearing time and comfort.

Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A

2002 ◽  
Vol 25 (2) ◽  
pp. 219-228 ◽  
Author(s):  
John A. Chaddock ◽  
Michael H. Herbert ◽  
Roger J. Ling ◽  
Frances C.G. Alexander ◽  
Sarah J. Fooks ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Clostridium Botulinum ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Expression And Purification ◽  
Catalytically Active ◽  
Derivatives Of
Sign in / Sign up

Export Citation Format

Share Document